TY - JOUR
T1 - Interferon Gamma-Induced Protein (IP-10) as Potential Biomarker for Cancer-Related-Fatigue: Results from a 6-month Randomized Controlled Trial
AU - ter Veer, Emil
AU - Prinsen, Hetty
AU - Sprangers, Mirjam A. G.
AU - Zwinderman, Koos A. H.
AU - Bleijenberg, Gijs
AU - van der Pouw Kraan, Tineke C. T. M.
AU - de Vries, I. Jolanda M.
AU - Wierenga, Eddy A.
AU - van Laarhoven, Hanneke W. M.
PY - 2018
Y1 - 2018
N2 - We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker. Trial registration: This study is registered at ClinicalTrials.gov (NCT01096641).
AB - We examined if serum concentrations Interferon gamma-induced protein (IP-10) is a potential clinical biomarker for cancer-related-fatigue (CRF). Fatigue scores and IP-10 concentrations were measured from curatively treated fatigued cancer patients randomized to either cognitive behavioral therapy (CBT, n = 26) or waiting-list (WL, n = 13). No correlation was found between baseline IP-10 level and fatigue severity and no significant differences in IP-10 serum levels were observed between fatigued and matched non-fatigued patients (n = 22). Relative changes in IP-10 concentrations from baseline to six-month follow-up were not significantly different between the CBT and WL conditions. In this study, IP-10 showed low potential as clinical CRF biomarker. Trial registration: This study is registered at ClinicalTrials.gov (NCT01096641).
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85053337092&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/30188739
U2 - https://doi.org/10.1080/07357907.2018.1499933
DO - https://doi.org/10.1080/07357907.2018.1499933
M3 - Article
C2 - 30188739
SN - 0735-7907
VL - 36
SP - 371
EP - 377
JO - Cancer Investigation
JF - Cancer Investigation
IS - 7
ER -